Oculis Holding AG
OCS · NASDAQ
Company research
Oculis Holding AG (Nasdaq: OCS) is a global clinical-stage biopharmaceutical company headquartered in Zug, Switzerland, purposefully driven to save sight and improve eye care by developing innovative topical drug candidates for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's lead product candidate, OCS-01, is a topical dexamethasone OPTIREACH formulation currently in Phase 3 clinical trials for the treatment of diabetic macular edema, while OCS-02, a topical biologic single-chain antibody fragment candidate, is advancing through Phase 2b clinical trials for dry eye disease. Rounding out its differentiated pipeline, OCS-05 is a disease-modifying neuroprotective agent being developed for acute optic neuritis and a broad range of neuro-ophthalmic disorders including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Founded in 2017 and led by CEO Dr. Riad Sherif, the company operates internationally with a presence in the U.S., Europe, and Iceland, and carries a market capitalization of approximately $667 million USD.
Research reports
Fundamental visual report that frames Oculis as a high-growth but still unprofitable clinical-stage biopharma, emphasizing forecast revenue growth above market rates, a cash runway into the medium term, and the central role of OCS-01 as the main value driver while flagging execution and funding risks common to pre-commercial biotech.
Investing.com (InvestingPro) · June 1, 2026How Fair Value analysis helped investors avoid a 42% loss in OculisNarrative research piece showing how Fair Value models identified OCS as significantly overvalued around 25.22 USD versus an intrinsic value estimate near 16.31 USD, and how subsequent Phase 3 trial failure and analyst target cuts led to a roughly 42% share-price drawdown; it stresses valuation discipline, deteriorating fundamentals, and the risk of paying a premium for pre-revenue biotech.
Tomorrow Terminal · May 30, 2026Oculis Holding AG (OCS) Stock Analysis: AI Research & Price TargetAI-generated but structured equity research report on Oculis that lays out bull, base, and bear price scenarios (12, 24, and 38 USD), arguing that the Phase 3 failure of lead asset OCS-01, rich valuation metrics, and earlier-stage remaining pipeline justify a cautious stance despite strong cash, diversified programs, and consensus Street targets that still imply large upside.
MarketBeat · March 30, 2026Oculis (NASDAQ:OCS) Trading Up 9.2% – Time to Buy?News-style analyst note that highlights a roughly 9.2% single‑day move in OCS shares and discusses whether the rally merits buying, putting the price action in the context of its clinical-stage profile, consensus “Moderate Buy” recommendations, and typical biotech volatility while reminding readers of the risks around trial outcomes and dilution.
Blank Capital Research · March 22, 2026OCS Stock Analysis — Is Oculis Holding AG a Buy? ★★★ RatingIndependent boutique report that evaluates whether Oculis is an attractive investment and assigns a “★★★” rating, reflecting a balanced view that recognizes the upside from its ophthalmology pipeline and cash resources while acknowledging material clinical, valuation, and funding risks typical of small-cap biopharma.